Cargando…

Myelodysplastic Syndromes with Isolated del(5q): Value of Molecular Alterations for Diagnostic and Prognostic Assessment

SIMPLE SUMMARY: Myelodysplastic syndromes with isolated del(5q) constitute the only MDS subtype defined by a cytogenetic alteration. The results of several clinical studies and the advances in new technologies have provided a better understanding of the biological basis of this disease. Specific gen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Acha, Pamela, Mallo, Mar, Solé, Francesc
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9688702/ https://www.ncbi.nlm.nih.gov/pubmed/36428627 http://dx.doi.org/10.3390/cancers14225531

Ejemplares similares

Analysis of Intratumoral Heterogeneity in Myelodysplastic Syndromes with Isolated del(5q) Using a Single Cell Approach
por: Acha, Pamela, et al.
Publicado: (2021)

Genetic Aspects of Myelodysplastic/Myeloproliferative Neoplasms
por: Palomo, Laura, et al.
Publicado: (2021)

TP53 and MDM2 single nucleotide polymorphisms influence survival in non-del(5q) myelodysplastic syndromes
por: McGraw, Kathy L., et al.
Publicado: (2015)

Van den Berghe's 5q- syndrome and myelodysplastic syndrome with isolated del(5q)
por: Lima, Diego Silva, et al.
Publicado: (2015)

Targeted deep sequencing of CD34+ cells from peripheral blood can reproduce bone marrow molecular profile in myelodysplastic syndromes
por: Martin, Roman, et al.
Publicado: (2018)

Regions of homozygosity confer a worse prognostic impact in myelodysplastic syndrome with normal karyotype
por: Mallo, Mar, et al.
Publicado: (2023)

Molecular markers demonstrate diagnostic and prognostic value in the evaluation of myelodysplastic syndromes in cytopenia patients
por: He, Rong, et al.
Publicado: (2022)

Diagnostics and Prognostication of Myelodysplastic Syndromes
por: Zini, Gina
Publicado: (2017)

Polish experience of lenalidomide in the treatment of lower risk myelodysplastic syndrome with isolated del(5q)
por: Butrym, Aleksandra, et al.
Publicado: (2015)

Images from the Haematologica Atlas of Hematologic Cytology: myelodysplastic syndrome with isolated del(5q)
por: Invernizzi, Rosangela
Publicado: (2022)

Incidence and prognostic impact of U2AF1 mutations and other gene alterations in myelodysplastic neoplasms with isolated 20q deletion
por: Castillo, Martín I., et al.
Publicado: (2023)

The Secondary Myelodysplastic Neoplasms (MDS) Jigsaw
por: Calvete, Oriol, et al.
Publicado: (2023)

Pathophysiologic and clinical implications of molecular profiles resultant from deletion 5q
por: Adema, Vera, et al.
Publicado: (2022)

PB1912: MYELODYSPLASTIC SYNDROME WITH ISOLATED 5Q DELETION AND ASSOCIATED 5Q DELETION TO 13Q DELETION
por: Bouayed Abdelmoula, N., et al.
Publicado: (2022)

A Case of Near-triploidy in Myelodysplastic Syndrome with del(5q) Combined with del(1p) and del(13q)
por: Kim, Bo-Ram, et al.
Publicado: (2012)

Del(5q) myelodysplastic syndrome combined with pure red cell aplasia
por: Park, Joowon
Publicado: (2018)

Successful Treatment of Concurrently Diagnosed Multiple Myeloma and Myelodysplastic Syndrome With Isolated Del(5q) With Lenalidomide, Bortezomib, and Dexamethasone
por: Washington, Nyomi R, et al.
Publicado: (2021)

P695: SINGLE-CELL MULTIOMICS ANALYSIS OF MYELODYSPLASTIC SYNDROME PREDICTS CLINICAL RESPONSE TO TREATMENT WITH DNA DEMETHYLATION AGENT
por: Campillo-Marcos, Ignacio, et al.
Publicado: (2023)

Practical Strategies for Management of Lenalidomide-Associated Cytopenias in Myelodysplastic Syndromes With del(5q)
por: Kurtin, Sandra E., et al.
Publicado: (2017)

Identification of Lenalidomide Sensitivity and Resistance Mechanisms in Non-Del(5q) Myelodysplastic Syndromes
por: Drusbosky, Leylah M., et al.
Publicado: (2020)

Del(5q) and inv(3) in myelodysplastic syndrome: A rare case report
por: Liang, Hai-Ping, et al.
Publicado: (2022)

Genomic Copy Number Variations in the Myelodysplastic Syndrome and Acute Myeloid Leukemia Patients with del(5q) and/or -7/del(7q)
por: Zhang, Rui, et al.
Publicado: (2015)

Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes
por: Sauta, Elisabetta, et al.
Publicado: (2023)

Complex karyotype in myelodysplastic syndromes: Diagnostic procedure and prognostic susceptibility
por: Shahjahani, Mohammad, et al.
Publicado: (2019)

CSNK1A1 mutations and gene expression analysis in myelodysplastic syndromes with del(5q)
por: Bello, Erica, et al.
Publicado: (2015)

Validation of the IPSS-R in lenalidomide-treated, lower-risk myelodysplastic syndrome patients with del(5q)
por: Sekeres, M A, et al.
Publicado: (2014)

The impact of lenalidomide exposure on response and outcomes in patients with lower-risk myelodysplastic syndromes and del(5q)
por: Sekeres, Mikkael A., et al.
Publicado: (2018)

Lenalidomide for anemia correction in lower-risk del(5q) myelodysplastic syndrome patients of Asian ethnicity
por: Hong, Junshik, et al.
Publicado: (2021)

The Prognostic Value of Pretherapy Peripheral Blood Inflammatory Indices in Myelodysplastic Syndromes
por: Shi, Cong, et al.
Publicado: (2022)

Prognostic value of the controlling nutritional status score in patients with myelodysplastic syndromes
por: Chen, Qiuni, et al.
Publicado: (2022)

Early lenalidomide treatment for low and intermediate‐1 International Prognostic Scoring System risk myelodysplastic syndromes with del(5q) before transfusion dependence
por: Oliva, Esther N., et al.
Publicado: (2015)

Myelodysplastic Syndromes with Isolated 20q Deletion: A New Clinical–Biological Entity?
por: Campagna, Alessia, et al.
Publicado: (2022)

Molecular Drivers of Myelodysplastic Neoplasms (MDS)—Classification and Prognostic Relevance
por: Hoff, Fieke W., et al.
Publicado: (2023)

Myelodysplastic disorders carrying both isolated del(5q) and JAK2(V617F) mutation: concise review, with focus on lenalidomide therapy
por: Musto, Pellegrino, et al.
Publicado: (2014)

Favorable prognostic phenotype in myelodysplastic syndrome with der(1;7)(q10;p10)
por: Horio, Tomohiro, et al.
Publicado: (2020)

Complete Remission of del(5q) Myelodysplastic Syndrome after 7 Days of Lenalidomide Therapy Gives an Alert!
por: Al-Jafar, Hassan A., et al.
Publicado: (2012)

Short- and long-term benefits of lenalidomide treatment in patients with lower-risk del(5q) myelodysplastic syndromes
por: Komrokji, R. S., et al.
Publicado: (2016)

Impact of somatic mutations on response to lenalidomide in lower-risk non-del(5q) myelodysplastic syndromes patients
por: Santini, Valeria, et al.
Publicado: (2020)

Prognostic Value of Thrombocytopenia in Myelodysplastic Syndromes After Hematopoietic Stem Cell Transplantation
por: Wang, Hong, et al.
Publicado: (2022)

Mutational Profile Enables the Identification of a High-Risk Subgroup in Myelodysplastic Syndromes with Isolated Trisomy 8
por: Toribio-Castelló, Sofía, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_2h1qgccl777eim7rv3s7u7kmk5